Sagimet Biosciences Inc. (SGMT)
2.21
-0.06 (-2.64%)
At close: Apr 10, 2025, 3:59 PM
2.23
0.66%
After-hours: Apr 10, 2025, 07:56 PM EDT
-2.64% (1D)
| Bid | 2.22 |
| Market Cap | 67.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.57M |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | -1.53 |
| Forward PE | -1.31 |
| Analyst | Buy |
| Ask | 2.23 |
| Volume | 310,349 |
| Avg. Volume (20D) | 806,403.7 |
| Open | 2.23 |
| Previous Close | 2.27 |
| Day's Range | 2.08 - 2.29 |
| 52-Week Range | 1.73 - 7.38 |
| Beta | 2.43 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol SGMT
Website https://sagimet.com
Analyst Forecast
According to 6 analyst ratings, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 1299.55% from the latest price.
Stock Forecasts2 months ago
+10%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
-13.95%
Sagimet Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results.
